Despite the demonstrated effectiveness of several small molecules as PDK1 and Akt inhibitors both in vitro and in vivo, only a few have progressed to clinical trials for cancer treatment purposes (Landel et al., 2020). This evidence concerns the gene AKT1 and cancer.